Randomized Study Comparing Intravenous Busulfan (i.v. Bu; Busilvex [Registered Trademark]) plus Fludarabine (Buflu) Versus Intravenous Busulfan Plus Cyclophosphamide (Bucy2) As Conditioning Regimens Prior To Allogeneic Hematopoietic Stem Cell Transplantation (ALLOHSCT) In Patients (from 40 to 55 years) With Acute Myeloid Leukemia (AML) In Complete Remission (CR).

This study is comparing two types of chemotherapy preparation (conditioning) given before a stem cell transplant in patients aged 40 to 55 with acute myeloid leukaemia (a type of blood cancer) that is currently in remission. One preparation uses busulfan plus fludarabine (BuFlu), which is newer and thought to be less toxic. The other uses the older standard of busulfan plus cyclophosphamide (BuCy2). Researchers want to find out which combination leads to fewer deaths related to the transplant procedure itself. You may be eligible if: - You are between 40 and 55 years old - You have been diagnosed with acute myeloid leukaemia (AML) that is currently in complete remission - A matched stem cell donor is available (sibling or unrelated) - Your performance status is reasonable (ECOG score below 3) - Your heart, lungs, liver, and kidneys are functioning well enough You may NOT be eligible if: - You have a previous history of stem cell transplantation - You have poorly controlled high blood pressure - You have had a heart attack in the past 12 months - You are pregnant - You are HIV positive or have active hepatitis - You have significant organ dysfunction (heart, lungs, liver, or kidneys) Talk to your doctor about whether this trial might be right for you.